| 证券代码 | DOVA.O |
| 证券名称 | 多瓦制药 |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2017-06-29 |
| 首发价格(元) | 17 USD |
| 首发数量(股) | 4415000 |
| 首发募资额(元) | 75,055,000.00 USD |
| 首发主承销商 | J.P. Morgan Securities LLC,Jefferies LLC,Leerink Partners LLC |
| 货币单位 | USD |
| 公司名称 | Dova Pharmaceuticals, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 240 Leigh Farm Road, Suite 245, Durham, North Carolina, USA |
| 成立日期 | 2016-03 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.dova.com |
| 电话 | +1 (919) 748-5975 |
| 传真 | - |
| 公司简介 | Dova Pharmaceuticals, Inc. is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s proprietary pipeline includes one commercial product, DOPTELET, for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. |